Search

Floating LiDAR systems (FLSs) may replace conventional offshore met masts, and they have been developed well in Europe. However, before using them in Japan, we must determine whether they demonstrate the same performance under the unique East-Asian meteorological and oceanographic conditions. Therefore, herein, we investigate the performance of FLSs by focusing on the differences among models. Four independent wind datasets from three FLSs were simultaneously verified against a reference met mast and vertical LiDAR at a Japanese site. The data availability was confirmed to vary from 62.7 to 98.0% over the period at 63 m. This was strongly affected by the system availability of the buoy and LiDAR, suggesting that buoy system robustness is key to better campaigns with higher data availability. The 10 min averaged wind speed and direction largely satisfied the Carbon Trust's key performance indicators, with a low sensitivity to wave conditions depending on the buoy shape. The standard deviation of the wind speed and turbulence intensity had poorer accuracy than that of the 10 min averaged statistics because of the wave-induced buoy motion, especially for small buoys. In short, this paper provides an overview of a measurement by FLS in Japan. Also, the unique verification with multiple units suggests the need for a low-motion buoy or motion compensation to improve the measurement accuracy of the turbulence component. [ABSTRACT FROM AUTHOR]

The purpose of this study was to retrospectively evaluate the severity and the characteristics of dysphagia using videofluoroscopic swallowing studies (VFSS) in long-lasting dysphagia patients developing after thoracotomy performed for pulmonary resection. Eleven patients (10 men and 1 woman, average age 67 ± 6.6 years; the average operation time in the patients was 507 min) were selected from among patients who developed dysphagia after undergoing thoracotomy for pulmonary resection between January 2009 and December 2012. The videofluoroscopic dysphagia scale (VDS) at 1 month postoperatively was used as a representative of parameters examined by the VFSS. The score on the functional oral intake scale (FOIS) was determined to evaluate the swallowing capacity at 1 and 3 months postoperatively. Most of the patients showed improvement of FOIS score at 3 months postoperatively. The patients showed mainly pharyngeal dysfunction. In spite of preserving the swallowing reflex, abnormalities of the residue in the vallecula and pyriform sinus and penetration were relatively frequent. Perioperative factors (age, %VC, FEV, operation time, length of ICU stay) and FOIS were investigated to determine their relationships with the VDS score. While it showed no relationship with the age, lung function, operation time, and length of ICU stay, the VDS score was found to be significantly associated with the FOIS score at 3 months postoperatively. Evaluation by VFSS after lung surgery is useful to predict the prognosis of swallowing difficulty. [ABSTRACT FROM AUTHOR]

Patients with metastatic ovarian cancer (OvCa) have a 5-year survival rate of <30% due to the persisting dissemination of chemoresistant cells in the peritoneal fluid and the immunosuppressive microenvironment in the peritoneal cavity. Here, we report that intraperitoneal administration of β-glucan and IFNγ (BI) induced robust tumor regression in clinically relevant models of metastatic OvCa. BI induced tumor regression by controlling fluid tumor burden and activating localized antitumor immunity. β-glucan alone cleared ascites and eliminated fluid tumor cells by inducing intraperitoneal clotting in the fluid and Dectin-1-Syk-dependent NETosis in the omentum. In omentum tumors, BI expanded a novel subset of immunostimulatory IL27+ macrophages and neutralizing IL27 impaired BI efficacy in vivo. Moreover, BI directly induced IL27 secretion in macrophages where single agent treatment did not. Finally, BI extended mouse survival in a chemoresistant model and significantly improved chemotherapy response in a chemo-sensitive model. In summary, we propose a new therapeutic strategy for the treatment of metastatic OvCa., (© 2024 Murphy et al.)

Patients with metastatic ovarian cancer (OvCa) have a 5-year survival rate of less than 30% due to persisting dissemination of chemoresistant cells in the peritoneal fluid and the immunosuppressive microenvironment in the peritoneal cavity. Here, we report that intraperitoneal administration of β-glucan and IFNγ (BI) induced robust tumor regression in clinically relevant models of metastatic OvCa. BI induced tumor regression by controlling fluid tumor burden and activating localized antitumor immunity. β-glucan alone cleared ascites and eliminated fluid tumor cells by inducing intraperitoneal clotting in the fluid and Dectin-1-Syk-dependent NETosis in the omentum. In omentum tumors, BI expanded a novel subset of immunostimulatory IL27+ macrophages and neutralizing IL27 impaired BI efficacy in vivo . Moreover, BI directly induced IL27 secretion in macrophages where single agent treatment did not. Finally, BI extended mouse survival in a chemoresistant model and significantly improved chemotherapy response in a chemo-sensitive model. In summary, we propose a new therapeutic strategy for the treatment of metastatic OvCa., Competing Interests: Disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Hepatic abscesses are divided into bacterial and amoebic types. Although the prognosis of bacterial liver abscesses has improved owing to progress in drainage techniques and antimicrobial agents, poor outcomes remain common. While there have been some reports of amoebic liver abscesses complicated by thrombosis, bacterial liver abscesses and subsequent thrombus in the right atrium are very rare. We herein report the case of an 82-year-old man. He had suffered acute obstructive suppurative cholangitis 10 months previously, and bile culture yielded Enterococcus faecalis. In the present case, a right atrial thrombus caused by a bacterial liver abscess was observed and the causative organism was thought to be Enterococcus faecalis, for which was detected in a blood culture was positive. The patient was successfully treated with hepatic abscess drainage and surgical right atrial thrombectomy under cardiopulmonary bypass with a beating heart.

Objectives: To evaluate the effect of a self-controlled vocal exercise in elderly people with glottal closure insufficiency., Design: Parallel-arm, individual randomized controlled trial., Methods: Patients who visited one of 10 medical centers under the National Hospital Organization group in Japan for the first time, aged 60 years or older, complaining of aspiration or hoarseness, and endoscopically confirmed to have glottal closure insufficiency owing to vocal cord atrophy, were enrolled in this study. They were randomly assigned to an intervention or a control group. The patients of the intervention group were given guidance and a DVD about a self-controlled vocal exercise. The maximum phonation time which is a measure of glottal closure was evaluated, and the number of patients who developed pneumonia during the six months was compared between the two groups., Results: Of the 543 patients enrolled in this trial, 259 were allocated into the intervention group and 284 into the control; 60 of the intervention group and 75 of the control were not able to continue the trial. A total of 199 patients (age 73.9 ±7.25 years) in the intervention group and 209 (73.3 ±6.68 years) in the control completed the six-month trial. Intervention of the self-controlled vocal exercise extended the maximum phonation time significantly ( p < 0.001). There were two hospitalizations for pneumonia in the intervention group and 18 in the control group, representing a significant difference ( p < 0.001)., Conclusion: The self-controlled vocal exercise allowed patients to achieve vocal cord adduction and improve glottal closure insufficiency, which reduced the rate of hospitalization for pneumonia significantly., Clinical Trial: gov Identifier-UMIN000015567.